Nucleic acid aptamers and their complimentary antidotes: Entering an era of antithrombotic pharmacobiologic therapy

Hamostaseologie

Volumn 27, Issue 5, 2007, Pages 378-382

  Becker, R C ^a   Oney, S ^b,c   Becker, K C D ^d   Rusconi, C P ^e   Sullenger, B ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Duke Translational Research Institute   (United States)

^d BOSTON UNIVERSITY   (United States)

^e Regado Biosciences   (United States)

Author keywords

Antithrombotic agents; Nucleic acid aptamers; Oligonucleotides; Pharmacobiologic therapy

Indexed keywords

BLOOD CLOTTING FACTOR; FIBRINOLYTIC AGENT;

ARTICLE; CLINICAL TRIAL; FIBRINOLYTIC THERAPY; HUMAN; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

BLOOD COAGULATION FACTORS; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; THROMBOLYTIC THERAPY;

EID: 38749106637     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Becker RC, Rusconi C, Sullenger B. Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb Haemost 2005; 93: 1014-1020.
2. Howard EL, Becker KC, Rusconi CP et al. Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 2007; 27: 722-727.
3. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249: 505-510.
4. Gold L, Polisky B, Uhlenbeck O et al. Diversity of oligonucleotide functions. Ann Rev Biochem 1995; 64: 763-797.
5. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346: 818-822.
6. Rusconi CP, Roberts JD, Pitoc GA et al. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 2004; 22: 1423-1428.
7. Rusconi CP, Scardino E, Layzer J et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002; 419: 90-94.
8. Dausse E, Cazenave C, Rayner B et al. In vitro selection procedures for identifying DNA and RNA aptamers targeted to nucleic acids and proteins. Meth Mol Biol 2005; 288: 391-410.
9. Layzer JM, Sullenger BA. Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides 2007; 17: 1-11.
10. Nimjee SM, Keys JR, Pitoc GA et al. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther 2006; 14: 408-415.
11. Dyke CK, Steinhubl SR, Kleiman NS et al. Firstin-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drugantidote pair for the controlled regulation of factor IXa activity. Circulation 2006; 114: 2490-2497.
12. Andrews RK, Gardiner EE, Shen Y et al. Glycoprotein Ib-IX-V. Int J Biochem Cell Biol 2003; 35: 1170-1174.
13. Hodivala-Dilke KM, McHugh KP, Tsakiris DA et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999; 103: 229-238.
14. Smyth SS, Reis ED, Vaananen H et al. Variable protection of beta 3-integrin-deficient mice from thrombosis initiated by different mechanisms. Blood 2001; 98: 1055-1062.
15. Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci USA 2000; 97: 2803-2808.
16. Oney S, Nimjee SM, Layzer JM et al. Antidotecontrolled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides 2007; in press.